Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909161 | 0.90 | TYMS (0.45) | TYMS | |
| SCHEMBL15725695 | 0.87 | TYMS (0.41) | TYMS | |
| SCHEMBL21580549 | 0.82 | TYMS (0.46) | TYMS | |
| SCHEMBL22894241 | 0.77 | TYMS (0.43) | TYMS | |
| SCHEMBL23010140 | 0.75 | — | — | |
| SCHEMBL20707148 | 0.74 | TYMS (0.39) | TYMS | |
| SCHEMBL11342773 | 0.73 | TYMS (0.70) | TYMS | |
| SCHEMBL30888409 | 0.72 | TYMS (0.64) | TYMS | |
| Thymidine Monophosphate SCHEMBL8662711 | 0.71 | TYMS (0.66) | TYMS | |
| SCHEMBL25469598 | 0.71 | TK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084590-B2 | Labelled nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20100311178-A1 | Labelled nucleotides | ILLUMINA CAMBRIDGE LIMITED | 2010-12-09 | — | — | US | disclosed |
| US-7795424-B2 | Labelled nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2010-09-14 | — | — | US | disclosed |
| US-20090062145-A1 | Labelled nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311178-A1 | Labelled nucleotides | NUDT1, DUT, NT5C2 | TYMS 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.